High Quality sarms powder lgd 3303 with 99% Purity cas:1165910-22-4

Product link to:https://www.astersteroids.com/high-quality-sarms-powder-lgd-3303-with-99-purity-cas1165910-22-4/

Sarms LGD-3303
Purity:99% HPLC
Packing:10g,100g,500g and 1kg
Min Order: Powder---10gram
Payment:Bitcoin,Moneygram and Wester Union
Lead time:24hours after received payment
Safe shipping to US and most of Europe country

Product Name: LGD-3303
CAS:1165910-22-4
MF:C16H14ClF3N2O
MW:342.7433696
Appearance: Light Yellow powder
Purity: 99.% min
Package: 10g/bag or as customers’request.
Test Method: HPLC

In order to determine plasma concentrations, the LGD-3303 standard solution was added to blank rat plasma; calibration standards were constructed from 0.001 to 10 μg/ml; 250 μl acetonitrile containing LGD-2226 was used as an internal standard (Miner et al., 2007). 50 μl of the calibration standard and 50 μl of the plasma sample were extracted by protein precipitation. After centrifugation, the supernatant was analyzed by liquid chromatography (LC) for LGD-3303 followed by tandem mass spectrometry. To determine the tissue concentration, the standard solution of LGD-3303 was added to blank rat tissues in a 2:1 ratio (v/w) standard solution and tissue. A calibration standard (from 0.01-5 μg/ml) was constructed in an extraction solution [Acetonitrile/water = 70:30 (v/v)] containing LGD-2226 as an internal standard. The tissue sample was extracted with 2 volumes of an extraction solution containing an internal standard. After overnight extraction, the supernatant was analyzed for LGD-3303 by LC tandem mass spectrometry. The analysis was performed by electrospray ionization mass spectrometry (MS) using an Applied Biosystems API 4000 or API 4000/Q-trap (Applied Biosystems, Foster City, CA). Samples were analyzed by injecting 10 to 20 μl of the supernatant into the LC/MS instrument. The LC instrument was equipped with a C8 octyl, MOS guard column (4 x 2 mm; Phenomenex, Torrance, CA) and a Gemini C6-phenyl column (50 x 2.0 mm, 5 [mu]m; Phenomenex). The mobile phases A and B are respectively 0.1% formic acid in H2O and 0.1% formic acid in acetonitrile. A multi-reaction monitoring scan using 343.1 / 245.3 atomic mass units was monitored in positive mode.

Benefit:LGD-3303 has been developed to help address a wide range of conditions. However, the most important is its ability to maintain the beneficial effects of androgens in improving muscle mass and bone density without the side effects. Although the selective mechanism of LGD-3303 and other SARMs is not yet clearly understood even with ongoing research, it is clearly a big leap from the usual supplyment.

Application:LGD-3303 is a selective androgen receptor modulator (SARM) that comes with impeccable oral bioavailability. It is categorized as a selective agonist designed for the androgen receptor. LGD-3303 has androgenic effects and at the moment it is being researched as a possible solution to treat osteoporosis.